JPRN-jRCTs041210016招募中未知
A randomized, open-label, parallel-group controlled trial investigating the efficacy and safety of long-term low-dose Dienogest in patients with dysmenorrhea due to endometriosis
Kikuno Kyoko0 个研究点目标入组 88 人开始时间: 2021年5月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •1.Patients who have been diagnosed with endometriosis (ovarian endometriotic cyst) and do not plan to undergo surgery
- •2. Patients with dysmenorrhea
- •3. Patients who plan to continue using Dienogest for more than 48 weeks.
- •4.Patients over 20years old to premenopausal at the time of consent
- •5.Patients who have written consent to participate in this study
排除标准
- •1.Patients who have been diagnosed with endometriosis (ovarian endometriotic cyst) and do not plan to undergo surgery
- •2. Patients with dysmenorrhea
- •3. Patients who plan to continue using Dienogest for more than 48 weeks.
- •4.Patients over 20years old to premenopausal at the time of consent
- •5.Patients who have written consent to participate in this study
研究者
相似试验
尚未招募
2 期
Clinical study to compare the effect of Unani drug with aceclofenac in joints paiCTRI/2019/05/019237Central Research Institute of Unani Medicine Hyderabad
尚未招募
3 期
A clinical trial to study effect of Madhav Rasayan tablets in COVID 19 patientsCTRI/2020/11/029444Shri Vishwavati Ayurved Chikitsalaya and Research Centre
尚未招募
2 期
Ayurvedic management of primary obesity - A clinical studyCTRI/2022/06/043128Dr Sarjita Tusharbhai Patel
进行中（未招募）
不适用
A controlled open label randomized parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients after kidney transplant. - TAKT- Treatment of Anaemia after Kidney TransplantEUCTR2007-003955-35-ITROCHE318
进行中（未招募）
不适用
A controlled open label randomised parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients after kidney transplant.This study is being performed to investigate the efficacy, safety and tolerability of administration of MIRCERA to anaemic patients with chronic kidney disease and reduced renal function following renal transplant, who are not expected to be considered for dialysis during the course of the study. Hereafter for the purposes of this protocol this population will be referred to as ‘post renal transplant anaemia’ patients.MedDRA version: 9.1Level: PTClassification code 10058116Term: Nephrogenic anaemiaEUCTR2007-003955-35-DEF. Hoffmann-La Roche Ltd318